Morgan Stanley lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $7 from $11 and keeps an Underweight rating on the shares. 2025 total revenue guidance of $75M-$90M was below expectations and implies declining growth of 6% year-over-year at the mid-point, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics price target lowered to $21 from $23 at Oppenheimer
- Positive Growth Prospects and Strategic Developments Drive Buy Rating for Y-Mabs Therapeutics
- Y-mAbs Therapeutics Reports 2024 Financial Results
- Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results
- Morning Movers: Target, Best Buy slipping after earnings as tariffs take effect